Breaking News

Veranova to Invest $30M in Devens, MA Facility

Initiates a significant expansion of its ADC and highly potent compound development and manufacturing capabilities.

Author Image

By: Charlie Sternberg

Associate Editor

Veranova, a developer and manufacturer of specialist and complex APIs for the pharmaceutical and biotech sectors, has initiated a significant expansion of its antibody-drug conjugate (ADC) and highly potent compound development and manufacturing capabilities at its Devens, MA facility. The estimated $30 million investment will build upon the site’s existing development and manufacturing capabilities and will address the growing demand for strong US-based capacity for ADCs and other potent sm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters